Several clinical investigations have revealed that ASPH upregulation correlated with poor prognosis in colon cancer [10], hepatocellular [11], non-small cell lung [12], and breast cancer [13], etc. The whole ASPH protein contains five domains, among which the C-terminal domain, as its main catalytic region, can hydroxylate epidermal growth factor (EGF)-like domains in numerous proteins, such as NOTCH and JAG, and serves as an antigenic epitope that can stimulate immunocytes [14,15]. The gene discussed is ASPH; the disease is breast carcinoma.